New insulin report highlights how incentives benefit middlemen, harm patients
The Senate Finance Committee has released a new report detailing findings of their investigation into the role that market dynamics play in the pricing of insulins. The report conclusions further solidify what we already know:perverse incentives in the market drove up insulin costs for patients.Some key details. Many insulins have experienced significant net price declines in recent years. (Source: The Catalyst)
Source: The Catalyst - January 22, 2021 Category: Pharmaceuticals Authors: Brian Newell Tags: Diabetes Out-of-Pocket Costs Pharmacy Benefit Managers Let's Talk About Cost Source Type: news

Key facts: The final rebate rule will be a positive change for patients
While drug middlemen are making billions of dollars in record profits at a time when millions of Americans are facing financial struggles, they are also suing to block the final rebate rule, a policy to lower out-of-pocket drug costs for patients. The fact is that the final rebate rule is a good policy for patients – one that policymakers and stakeholders have been carefully considering for years. (Source: The Catalyst)
Source: The Catalyst - January 19, 2021 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Part D Out-of-Pocket Costs Pharmacy Benefit Managers Source Type: news

ICYMI: Cancer death rate continues decline due to advances in treatment
For the second year in a row, The American Cancer Society (ACS) reports a record single-year decline in cancer death rates in the United States. Each year, ACS estimates the number of new cancer cases and deaths that will occur in the United States. For nearly 30 years, the trend towards fewer cancer deaths has been moving in a positive direction with fewer deaths year after year. In their latest report,Cancer Statistics 2021, data demonstrates cancer mortality decreased 2.4% from 2017 to 2018, surpassing the record single-year decline reported in the previous year. Overall, cancer death rates have fallen 31% since peaking...
Source: The Catalyst - January 19, 2021 Category: Pharmaceuticals Tags: Research and Development Cancer & D Focus Source Type: news

Research shows gene therapies can offer cost savings potential of up to $1.8M over five years for patients with certain blood diseases
Arecent analysis by Health Advances looks at two particularly burdensome hematological (or blood) diseases — beta thalassemia andhemophilia A— and finds that potential gene therapies in the pipeline could reduce per patient costs by as much as 41% and 90%, respectively, over five years. Research-based knowledge gained in recent years about the genetic foundation for these diseases has facilitated the pursuit of several promising gene t herapy approaches. (Source: The Catalyst)
Source: The Catalyst - January 15, 2021 Category: Pharmaceuticals Authors: Katie Koziara Tags: Rare Diseases Drug Cost New Era of Medicine The Value Collaborative Source Type: news

New data show retail medicine prices fell in 2019
In 2019, retail prescription medicine prices declined by 0.4%, on average, according to National Health Expenditures (NHE)data from the Centers for Medicare& Medicaid Services (CMS) published recently inHealth Affairs. While retail prescription medicine spending grew 5.7% that same year,this increase was due to more patients getting the medicines they need, not higher prices. (Source: The Catalyst)
Source: The Catalyst - January 13, 2021 Category: Pharmaceuticals Authors: Katie Koziara Tags: Let's Talk About Cost Source Type: news

Paper finds gaps in health data are a barrier to health equity
COVID-19 has laid bare racial disparities in the United States health system. For example, COVID-19 cases among Native Hawaiian / Pacific Islanders are up to 2.5 times higher as compared to whites. Similarly, the rate of COVID-19 related deaths among Black Americans and American Indian/Alaskan Natives aretwice as high as whites. A recent PhRMA paper finds that gaps in information on race, ethnicity and health are barriers to achieving health equity for many groups. (Source: The Catalyst)
Source: The Catalyst - January 11, 2021 Category: Pharmaceuticals Authors: Emily Donaldson Tags: Coronavirus Health Equity Source Type: news

New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
As part of PhRMA ’s continuing work to address health inequities, we are partnering with researchers tostudy hotspots of COVID-19 and chronic disease inequities in New York state.Reports this summer show that boroughs in New York City with the lowest per-person income and lowest number of employer establishments had the highest COVID-19 mortality rates. (Source: The Catalyst)
Source: The Catalyst - January 8, 2021 Category: Pharmaceuticals Authors: Jackie McRae Tags: Coronavirus Health Equity Source Type: news

American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
As the world has grappled with the current pandemic, there has been increased focus on biopharmaceutical manufacturing and its global supply chain. Many wondered whether the biopharmaceutical industry could ensure continued and uninterrupted supply of innovative medicines relied on by so many Americans, as well as develop and supply new treatments and vaccines to address the pandemic. We are nearly a year into this public health crisis, and the biopharmaceutical manufacturing industry has stepped up to help beat COVID-19 in more ways than one. Anew report from TEConomy Partners takes a closer look at what makes the U.S. bi...
Source: The Catalyst - December 21, 2020 Category: Pharmaceuticals Tags: Economic Impact Manufacturing STEM Coronavirus Source Type: news

End of year Part D reading List
Happy Holidays, Part D readers, and thank you for following along this year as we explored the impact of Medicare Part D and the important role the program plays for seniors and those with disabilities. (Source: The Catalyst)
Source: The Catalyst - December 18, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Part D Medicare Source Type: news

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
America ’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access to breakthrough therapies. Innovators are also relying on these strong protections to discover new medical advances that will keep patients healthy during this pandemic and after. (Source: The Catalyst)
Source: The Catalyst - December 18, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Intellectual Property IP Explained Coronavirus Source Type: news

Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients
TheNew York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry ’s commitment to the program. Today, we’re correcting the record.Fact: Manufacturers are still giving the 340B discounts, as required by law, to “covered entities”– more than 12,700 hospitals and clinics currently participating in the 340B program.Some companies have recently implemented changes to shipment of 340B drugs in response to decades of program failures, which is being mischaracterized by some. These companies ...
Source: The Catalyst - December 17, 2020 Category: Pharmaceuticals Tags: 340B Hospitals 340B Spotlight Source Type: news

Increasing diversity at investigator sites could increase minority participation in clinical trials
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - December 17, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Clinical Trials Health Equity Source Type: news

New report highlights biopharmaceutical industry ’s commitment to D & I
Today, PhRMA released a newreportprepared by TEConomy Partners, LLC that provides insights into the efforts of biopharmaceutical companies to advance diversity& inclusion (D&I) in the workplace, in the communities in which they operate and in the patient communities in which they serve. The report examines the state of accelerating demographic changes and persistent workforce disparities both broadly in corporate America and within the biopharmaceutical industry. The report compiles insights into how the biopharmaceutical industry is increasing opportunities and addressing workplace disparities for underrepresented...
Source: The Catalyst - December 17, 2020 Category: Pharmaceuticals Authors: Abigail Lore Tags: PhRMA Member Company Health Equity Source Type: news

Election insights: Voter priorities in the states
In the 2020 election, Americans nationwide cast their ballots withtwo major issues on their minds – the economy and coronavirus. Health care specific concerns centered on pre-existing conditions protections and rising out-of-pocket costs exacerbated by declining coverage. But how do these trends compare at the state level? (Source: The Catalyst)
Source: The Catalyst - December 17, 2020 Category: Pharmaceuticals Authors: Nick McGee Tags: Health Insurance Out-of-Pocket Costs COVID-19 Source Type: news

Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
This year our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. Outside of the novel coronavirus, major social issues have been brought to the forefront of public discourse. We understand that systematic racism is as real as any disease and our industry is not immune. We need to stand up to racism and injustice because failing to do so impacts our collective wellbeing. Our industry is committed to learning and leading us forward. (Source: The Catalyst)
Source: The Catalyst - December 16, 2020 Category: Pharmaceuticals Tags: Clinical Trials COVID-19 Health Equity Source Type: news

Insights from the election: Meeting voters where they are on health care
The 2020 election was defined by a wide range of unique, and in some cases, unprecedented factors. From a global pandemic to never before seen rates of mail-in ballot casting and record voter turnout across the country, this election cycle was unlike any other we have seen in recent history. Thus, it may not be surprising that in some cases where we saw candidates adhering too closely to a traditional campaign playbook, election outcomes turned out in ways we did not anticipate. (Source: The Catalyst)
Source: The Catalyst - December 15, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Out-of-Pocket Costs Coronavirus Source Type: news

Key takeaways from new GAO report on covered entities ’ lack of compliance with 340B requirements
In case you missed it,the Government Accountability Office (GAO) released a new report looking at the 340B program and the mechanisms the government has to help ensure compliance with the program ’s requirements. This is the latest in series of reports from the government watchdog that has raised concerns with 340B program integrity. Earlier this year, for example, GAO found it is likely that there are nongovernmental hospitals participating in 340B that arenot eligible for the program but have taken advantage of the lax oversight of 340B so they can reap the financial benefits of it (Source: The Catalyst)
Source: The Catalyst - December 15, 2020 Category: Pharmaceuticals Tags: 340B Source Type: news

Report: More than 1,300 medicines and vaccines in development to help fight cancer
Over the last 30 years, significant progress has been made in the fight against cancer. Researchers have expanded their understanding of how cancer develops and how to target medicines for specific cancer types. Since peaking in 1991, the death rate associated with cancerdeclined by 29%, which translates to 2.9 million fewer cancer deaths. The most recent data shows that between 2016 and 2017 alone, cancer death ratesdeclined by 2.2%, the largest single-year drop ever recorded. Despite the challenges imposed by the COVID-19 pandemic, this momentum continues with biopharmaceutical companies focusing on research and dev...
Source: The Catalyst - December 15, 2020 Category: Pharmaceuticals Tags: Medicines in Development Cancer New Era of Medicine & D Focus Source Type: news

New analysis finds stark difference in coverage of breast cancer medicines for seniors in the United States and England
In the United States, seniors and people with disabilities enjoy broad coverage of physician-administered medicines under Medicare Part B because the program relies on market competition to balance access, innovation and cost control. But the same cannot be said for patients in other countries. In fact, a new analysis from Avalere underscores the dangers of theMost Favored Nation (MFN) rule and other foreign reference pricing proposals. (Source: The Catalyst)
Source: The Catalyst - December 10, 2020 Category: Pharmaceuticals Tags: Medicare Part B CMMI International Reference Pricing Source Type: news

Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Business
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. (Source: The Catalyst)
Source: The Catalyst - December 9, 2020 Category: Pharmaceuticals Tags: Mental Health Coronavirus Source Type: news

Guest post: How COVID-19 underscores the importance of public confidence in vaccines
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - December 7, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Vaccines Coronavirus Source Type: news

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
America ’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access to breakthrough therapies. Innovators are also relying on these strong protections to discover new medical advances that will keep patients healthy during this pandemic and after. (Source: The Catalyst)
Source: The Catalyst - December 7, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Intellectual Property IP Explained Source Type: news

Guest Post: Bringing our best to the fight against COVID-19
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.Today, we are pleased to welcome a guest post Michel Pairet, a member of the Board of Managing Directors in charge of Innovation at Boehringer Ingelheim and Clive R. Wood, Global Head of Discovery Research. (Source: The Catalyst)
Source: The Catalyst - December 3, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Research and Development PhRMA Member Company Coronavirus Source Type: news

Final rebate rule represents right way to change Medicare
As Washington policymakers look to make changes to Medicare and our health care system overall, there are right ways and wrong ways to address the challenges that seniors and patients face. Indeed, as part of the 2020 election,voters made it clear what they want Washington policymakers to focus on: Addressing COVID-19 and concerns around pre-existing conditions and out-of-pocket costs. (Source: The Catalyst)
Source: The Catalyst - December 1, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Part D Medicare Out-of-Pocket Costs Source Type: news

No matter how you look at it, the Most Favored Nation rule is bad policy
Last month, the administration released the “Most Favored Nation” (MFN) rule, which allows foreign governments to decide the value of Part B medicines, while also likely limiting seniors’ access to existing medicines and discouraging investments in future treatments and cures. No matter how you look at it, the MFN rule is bad policy.  (Source: The Catalyst)
Source: The Catalyst - December 1, 2020 Category: Pharmaceuticals Tags: Medicare Part B CMMI International Reference Pricing Source Type: news

PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence
Systemic racism is as real as any disease, and our industry is not immune. This summer, in the wake of a national outcry for racial and social justice, our industry offered a firm stance –systemic racism is a disease. As a pharmacist and public health researcher whose motivation stems from advancing health equity – this statement makes me ponder the question, “How can our industry help break the harmful patterns of racial inequities?” One way PhRMA is advocating for health equity is through aCollaborative Actions to Reach Equity (CAREs) grant. (Source: The Catalyst)
Source: The Catalyst - November 24, 2020 Category: Pharmaceuticals Authors: Jackie McRae Tags: Health Equity Source Type: news

Committing to diversity, equity and inclusion: A call to action for clinical trials
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - November 19, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Clinical Trials Health Equity Source Type: news

Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds
Anew analysis by IQVIA looked at three cost-sharing assistance programs and found that from 2018 to 2020, 25% to 36% of patients discontinued treatment when they faced an unexpectedly high out-of-pocket cost of $1,500 or more in the middle of the plan year. These unexpected costs were caused by accumulator adjustment programs operated bypharmacy benefit managers and health plans. (Source: The Catalyst)
Source: The Catalyst - November 19, 2020 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Adherence Drug Cost Patient Assistance Programs Out-of-Pocket Costs Let's Talk About Cost Source Type: news

An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
This year our industry has worked tirelessly to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. At the same time, the nation ’s political environment remained turbulent, and systemic societal issues were brought to the forefront, all while we continued to socially distance and readjust our work and personal lives around the pandemic.   (Source: The Catalyst)
Source: The Catalyst - November 18, 2020 Category: Pharmaceuticals Tags: PhRMA Member Company Coronavirus Source Type: news

Just released: PhRMA members ’ new clinical trial diversity principles
Yesterday, PhRMA published first ever industry-wide principles on clinical trial diversity, a new chapter in the already existing “Principles on Conduct of Clinical Trials& Communication of Clinical Trial Results. ” These new principles have been approved by the PhRMA Board of Directors and will take effect in April 2021. (Source: The Catalyst)
Source: The Catalyst - November 18, 2020 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Clinical Trials Health Equity Source Type: news

Learning from history: How government price setting and other anti-innovation policies negatively impact biopharmaceutical R & D
Today, America leads the world in medical innovation because of our unique research ecosystem, but that wasn ’t always the case. Anew paper from NDP Analytics, “Will US Leadership in Biopharmaceutical R&D Continue? Consequences of Price Controls and Other Anti-Innovation Policies, ” takes a look at the positive and negative impacts that public policies can have on biopharmaceutical innovation – namely how the adoption of government price setting and other anti-innovation policies across Europe in the 1980s and 1990s pushed the locus of R&D investment away from the continent to countries with...
Source: The Catalyst - November 16, 2020 Category: Pharmaceuticals Tags: Research and Development International Reference Pricing Source Type: news

Deep dive: The issues that drove the 2020 vote
The 2020 election provided much-needed clarity on the issues that matter most to Americans. Here are three key takeaways: (Source: The Catalyst)
Source: The Catalyst - November 13, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Out-of-Pocket Costs Coronavirus Source Type: news

Understanding the emergency use authorization process for COVID-19 vaccines
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is working around the clock to develop safe and effective vaccines to prevent infection, as well as new therapies to treat the coronavirus. Awide range of approaches are currently being tested in robust clinical trials, with participants from all walks of life, to improve the odds that one or more vaccine candidates will be successful in meeting this pressing need. These trials look at how the immune system responds to a vaccine, its effectiveness in producing immunity and the safety profile. (Source: The Catalyst)
Source: The Catalyst - November 12, 2020 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Research and Development Vaccines Coronavirus Source Type: news

Recognizing America ’s Veterans
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - November 11, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Mental Illness Source Type: news

Guest Post: Recognizing America ’s Veterans
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - November 11, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Mental Illness Source Type: news

New video: See how strong IP protections lead to stronger treatments for patients
Intellectual property (IP) protections, including patents, are the foundation for biopharmaceutical innovation and the development of new treatments, cures and vaccines for patients. A strong IP system is what has allowed the American biopharmaceutical industry to become the world leader in new medicine development and has allowed us to make unprecedented strides in treating everything from acute leukemia to hepatitis C and more. (Source: The Catalyst)
Source: The Catalyst - November 9, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Intellectual Property IP Explained Source Type: news

PhRMA submits comments on ways to refocus the 340B program on America ’s vulnerable patients
In response to the Request for Input on Modernizing the 340B Drug Pricing Program issued by Representative Greg Walden and Senator Lamar Alexander,PhRMA has outlined a number of commonsense ways policymakers can get the 340B program back on track and refocused on patients. (Source: The Catalyst)
Source: The Catalyst - November 2, 2020 Category: Pharmaceuticals Tags: 340B Pharmacy Benefit Managers Source Type: news

ICYMI – Addressing health inequities: Biopharmaceutical companies are rising to the occasion
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - November 2, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Coronavirus Health Equity Source Type: news

ICYMI – Addressing health inequities: PhRMA is rising to the occasion
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - November 2, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: Coronavirus Health Equity Source Type: news

U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
As the United States biopharmaceutical industryworks around the clock to develop vaccines and treatments forCOVID-19, it ’s more important than ever that international trade policies facilitate patient access to innovative medicines. The pandemic has shed additional light on unsustainable barriers that threaten availability, research and development of much-needed treatments and cures. (Source: The Catalyst)
Source: The Catalyst - November 2, 2020 Category: Pharmaceuticals Authors: Douglas Petersen Tags: Trade Coronavirus Source Type: news

Voters want to address the real drivers of health care costs for patients and the system
COVID-19 has understandablyreshaped the health care conversation surrounding the upcoming election, withroughly one-fifth of voters citing the coronavirus pandemic as the priority issue heading into the 2020 presidential election. The global pandemic has also elevated personal health care anxieties, as voters have increasingly expressed concerns about their ability to access and afford the care they need when they need it. (Source: The Catalyst)
Source: The Catalyst - November 2, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Out-of-Pocket Costs Coronavirus Source Type: news

Guest post: Recognizing National Disability Employment Awareness Month
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - October 30, 2020 Category: Pharmaceuticals Authors: Guest Contributor Source Type: news

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
America ’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access to breakthrough therapies. Innovators are also relying on these strong protections to discover new medical advances that will keep patients healthy during this pandemic and after. (Source: The Catalyst)
Source: The Catalyst - October 28, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Source Type: news

Coming together to fight COVID-19: A conversation with Peter Anastasiou, Executive Vice President of Lundbeck
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. (Source: The Catalyst)
Source: The Catalyst - October 28, 2020 Category: Pharmaceuticals Tags: PhRMA Member Company Source Type: news

Safe drug disposal: National Prescription Drug Take Back Days and other year-round opportunities
The Pharmaceutical Product Stewardship Work Group (PPSWG) is a non-profit membership association for producers of pharmaceutical products. PPSWG was founded in 2014 to organize and facilitate cooperative efforts among pharmaceutical producers to address the disposal of unwanted, unused, or expired medicines from households. PPSWG ’s vision is to facilitate the appropriate and efficient disposal of unwanted, unused, or expired household medicines. (Source: The Catalyst)
Source: The Catalyst - October 23, 2020 Category: Pharmaceuticals Authors: Guest Contributor Source Type: news

Three things you should know about recent health care polling
Pollsters have been busy this year tracking public sentiment around the top issues of concern for voters. Recent public polling shows that voters priorities have shifted dramatically over the course of the year. With the election less than two weeks away, what is truly on the top of voter ’s minds? (Source: The Catalyst)
Source: The Catalyst - October 23, 2020 Category: Pharmaceuticals Authors: Priscilla VanderVeer Source Type: news

340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients
The 340B program – a safety-net federal drug program meant to help vulnerable Americans – has become dominated by many large hospitals and for-profit corporations with no clear evidence they are always helping needy patients. At a time when too many Americans struggle to access the medicines and care they need, it is alarming to see 340B being taken so far off course from what Congress intended as the program’s goal. (Source: The Catalyst)
Source: The Catalyst - October 23, 2020 Category: Pharmaceuticals Tags: 340B Hospitals 340B Spotlight Source Type: news

Study: Hospital and outpatient care are biggest drivers of health care spending differences between the United States and other countries
A number of past analyses have shown that hospitals drive U.S. health care spending. In fact, data released last year showed that theUnited States spends three times more per person on hospital care than on retail prescription medicines.A recent Peterson-KFF Health System Tracker analysis takes these findings a step further, concluding that hospital and outpatient care are not only the biggest drivers of U.S. health care spending but also the biggest drivers of the difference in health care spending between the United States and other developed countries. (Source: The Catalyst)
Source: The Catalyst - October 22, 2020 Category: Pharmaceuticals Authors: Gabby Migliara Source Type: news

How does Medicare Part D impact you?
Whether you are a direct beneficiary, a caregiver or simply an American taxpayer, Medicare Part D impacts you. The Medicare Part D program, which was created by the Medicare Modernization Act (MMA) of 2003 and formally implemented in 2006, provides affordable prescription drug coverage to seniors and people living with disabilities. Medicare Part D has long been widely touted as a success forpatients and members of the public alike. (Source: The Catalyst)
Source: The Catalyst - October 21, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Source Type: news

Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
Medicines are responsible for more than a third of the improvement in life expectancy from 1990 to 2015, according to a recentstudy published inHealth Affairs. This underscores the crucial role of biopharmaceutical innovation, as life expectancy increased 3.3 years during that time period. (Source: The Catalyst)
Source: The Catalyst - October 21, 2020 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Cancer HIV/AIDS Let's Talk About Cost Source Type: news